BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18690383)

  • 1. Abiotrophia spp. and Staphylococcus epidermidis endocarditis treated with daptomycin.
    Bishburg E; Ghuman D; Cohen A; Chan T; Nalmas S
    ScientificWorldJournal; 2008 Aug; 8():793-5. PubMed ID: 18690383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report.
    Duah M
    Ann Clin Microbiol Antimicrob; 2010 Feb; 9():9. PubMed ID: 20167084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Use of High-dose Daptomycin in a Child With Staphylococcus aureus Endocarditis.
    Prabhudesai S; Kanjani A; Nambi PS; Gnanasambandam S; Ramachandran B
    Pediatr Infect Dis J; 2016 May; 35(5):517-8. PubMed ID: 27074655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
    Sakoulas G; Eliopoulos GM; Alder J; Eliopoulos CT
    Antimicrob Agents Chemother; 2003 May; 47(5):1714-8. PubMed ID: 12709345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.
    Shah M; Murillo JL
    Ann Pharmacother; 2005 Oct; 39(10):1741-4. PubMed ID: 16144879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin and rifampin for the treatment of methicillin-resistant Staphylococcus aureus septic pulmonary emboli in the absence of endocarditis.
    Gomez EO; Jafary A; Dever LL
    Microb Drug Resist; 2010 Sep; 16(3):241-4. PubMed ID: 20617926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of mitral MRSA endocarditis using daptomycin].
    Senneville E; Beltrand E; Legout L; Leroy O; Fayad G
    Med Mal Infect; 2008 Dec; 38 Spec No 2():13-5. PubMed ID: 19185204
    [No Abstract]   [Full Text] [Related]  

  • 8. Indications for daptomycin use in endocarditis and pacemaker lead infection and outcomes in Leeds, UK.
    Sandoe J; Baig W
    Future Cardiol; 2012 Jul; 8(4):547-54. PubMed ID: 22871194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapidly destructive Staphylococcus epidermidis endocarditis.
    Zinkernagel AS; Speck RF; Ruef C; Zingg W; Berger-Bachi B; Springer B
    Infection; 2005 Jun; 33(3):148-50. PubMed ID: 15940416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis.
    Tascini C; Di Paolo A; Poletti R; Flammini S; Emdin M; Ciullo I; Tagliaferri E; Moter A; Menichetti F
    Antimicrob Agents Chemother; 2013 Jan; 57(1):601-2. PubMed ID: 23089753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between daptomycin susceptibility and teicoplanin resistance in Staphylococcus epidermidis.
    Watanabe S; Kawakami Y; Kimura H; Murakami S; Miyamoto H; Takatori S; Suemori K; Tanaka M; Tanaka A; Tanaka K; Tauchi H; Maki J; Araki H; Yamaguchi T
    Sci Rep; 2019 Dec; 9(1):18533. PubMed ID: 31811214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis.
    Rouse MS; Wilcox RM; Henry NK; Steckelberg JM; Wilson WR
    Antimicrob Agents Chemother; 1990 Feb; 34(2):273-6. PubMed ID: 2327776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus.
    Antony SJ
    Scand J Infect Dis; 2006; 38(4):293-5. PubMed ID: 16718933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides.
    Lichterfeld M; Ferraro MJ; Davis BT
    Int J Antimicrob Agents; 2010 Jan; 35(1):96. PubMed ID: 19896341
    [No Abstract]   [Full Text] [Related]  

  • 16. Staphylococcus epidermidis endocarditis treated with RP 59500 (quinapristin/dalfopristin).
    Larkin J; Busciglio L; Fontanet H; Gamouras G
    Clin Infect Dis; 1998 May; 26(5):1239-40. PubMed ID: 9597268
    [No Abstract]   [Full Text] [Related]  

  • 17. [Severe daptomycin-induced myopathy].
    Ferrera C; Vilacosta I; Vivas D; Olmos C
    Med Clin (Barc); 2012 Jun; 139(3):138-9. PubMed ID: 22285497
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.
    Voorn GP; Kuyvenhoven J; Goessens WH; Schmal-Bauer WC; Broeders PH; Thompson J; Michel MF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):487-93. PubMed ID: 8203842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM; Rojtman AD
    Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staphylococcus epidermidis endocarditis and mitral valve prolapse.
    Ferreira AC; Cohen J
    J Infect; 1988 Jan; 16(1):73-6. PubMed ID: 3367058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.